



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

on 11/26/01
By: Deborah NTS
Printed: Deborah Ellis

Docket No.: PF-0701 USA *3/a*

TECH CENTER 1600/2900

DEC 18 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tang et al.

Title: EXTRACELLULAR SIGNALING MOLECULES

Serial No.: 09/965,528

Filing Date: September 26, 2001

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 26, line 23, ending on page 27, line 2, with the following rewritten paragraph:

A₁
The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding EXCS. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:27-52 and to distinguish between SEQ ID NO:27-52 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express EXCS as a fraction of total tissues expressing EXCS. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing EXCS as a fraction of total tissues expressing EXCS. Of particular note is the expression of SEQ ID NO:30. This sequence is detected in six cDNA libraries, all of which were constructed independently using RNA isolated from prostate tissue.

(87776)

(1)

(09/965,528)